NanoViricides to Present at Spartan Capital Investor Conference 2025

NanoViricides, Inc., a leader in antiviral drug development, is presenting at the Spartan Capital Investor Conference 2025 in New York City. Scheduled for November 3rd, the presentation will be given by Anil R. Diwan, PhD, President and Executive Chairman, who will discuss the company's latest advancements, including their lead drug candidate, NV-387.

NV-387 is a broad-spectrum antiviral in the Phase II clinical stage. It targets multiple viruses by presenting binding sites that trick viruses into destruction. It is particularly promising for infections lacking current treatments, such as RSV, Measles, and MPox. Phase II trials are underway for MPox in the Democratic Republic of Congo, with impressive results in animal studies against Influenza.

The company's technology platform is expanding, developing candidates for Herpes and HIV. The platform enables drug delivery advancements and potential "rescue" of failed drugs. As such, NanoViricides positions itself as a key player in antiviral drug development.